https://www.selleckchem.com/pr....oducts/3-methyladeni
Testing and treatment data are available for 23 of these patients. Eleven patients were found to be low risk (9 as 1A, 2 as 1, 12 were found to be high risk (4 as 2A, 8 as 2. Decision-making was altered such that sentinel lymph node biopsy was omitted in 2 cases in which the patients were found to be low risk with age 65 years. In 8 cases of node-negative disease in genetically high-risk patients, surveillance measures were augmented with positron emission tomography/computed tomography. Utilization of 31-GEP is ongoing
Like
Comment
Share
